Novavax Inc (NVAX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Novavax Inc (NVAX) has a cash flow conversion efficiency ratio of 0.395x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-75.41 Million) by net assets ($-190.71 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Novavax Inc market capitalisation for the company's overall valuation and market capitalisation.
Novavax Inc - Cash Flow Conversion Efficiency Trend (1996–2025)
This chart illustrates how Novavax Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Novavax Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Novavax Inc ranked by their cash flow conversion efficiency. Explore earnings quality score of Novavax Inc to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Laurentian Bank Of Canada
TO:LB
|
0.171x |
|
OC OERL.CORP ADR 2 SF 1
F:OBH0
|
N/A |
|
Edelweiss Financial Services Limited
NSE:EDELWEISS
|
-0.125x |
|
Zhejiang Guyuelongshan Shaoxing Wine Co Ltd
SHG:600059
|
-0.006x |
|
Grupo Aeroméxico S.A.B. de C.V
MX:AEROMEX
|
-0.311x |
|
Zhejiang Jiangshan Chemical Co Ltd
SHE:002061
|
0.111x |
|
Zhejiang Fenglong Electric Co Ltd Class A
SHE:002931
|
0.012x |
|
Hunan Fazhan Industrial Co Ltd
SHE:000722
|
0.026x |
Annual Cash Flow Conversion Efficiency for Novavax Inc (1996–2025)
The table below shows the annual cash flow conversion efficiency of Novavax Inc from 1996 to 2025. View NVAX share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-127.75 Million | $-244.63 Million | 1.915x | +1268.96% |
| 2024-12-31 | $-623.84 Million | $-87.26 Million | 0.140x | -85.95% |
| 2023-12-31 | $-716.93 Million | $-713.97 Million | 0.996x | +51.82% |
| 2022-12-31 | $-634.08 Million | $-415.94 Million | 0.656x | +171.43% |
| 2021-12-31 | $-351.67 Million | $322.95 Million | -0.918x | -1253.93% |
| 2020-12-31 | $627.21 Million | $-42.54 Million | -0.068x | -109.23% |
| 2019-12-31 | $-186.02 Million | $-136.62 Million | 0.734x | -33.27% |
| 2018-12-31 | $-167.94 Million | $-184.82 Million | 1.101x | -19.27% |
| 2017-12-31 | $-101.73 Million | $-138.70 Million | 1.363x | -97.04% |
| 2016-12-31 | $-5.55 Million | $-255.47 Million | 46.063x | +10791.80% |
| 2015-12-31 | $292.67 Million | $-126.09 Million | -0.431x | -47.62% |
| 2014-12-31 | $229.62 Million | $-67.01 Million | -0.292x | -30.77% |
| 2013-12-31 | $203.23 Million | $-45.36 Million | -0.223x | +1.76% |
| 2012-12-31 | $80.24 Million | $-18.23 Million | -0.227x | +48.23% |
| 2011-12-31 | $53.85 Million | $-23.63 Million | -0.439x | +21.13% |
| 2010-12-31 | $59.05 Million | $-32.85 Million | -0.556x | -26.19% |
| 2009-12-31 | $74.47 Million | $-32.83 Million | -0.441x | +17.50% |
| 2008-12-31 | $45.49 Million | $-24.31 Million | -0.534x | -26.03% |
| 2007-12-31 | $63.06 Million | $-26.74 Million | -0.424x | -169.14% |
| 2006-12-31 | $94.00 Million | $-14.81 Million | -0.158x | -34.67% |
| 2005-12-31 | $49.65 Million | $-5.81 Million | -0.117x | +87.06% |
| 2004-12-31 | $33.28 Million | $-30.10 Million | -0.904x | -85.26% |
| 2003-12-31 | $35.94 Million | $-17.55 Million | -0.488x | +81.29% |
| 2002-12-31 | $8.07 Million | $-21.07 Million | -2.609x | -1471.21% |
| 2001-12-31 | $27.49 Million | $-4.57 Million | -0.166x | +47.38% |
| 2000-12-31 | $31.82 Million | $-10.04 Million | -0.316x | +76.12% |
| 1999-12-31 | $2.80 Million | $-3.70 Million | -1.321x | -10.12% |
| 1998-12-31 | $3.00 Million | $-3.60 Million | -1.200x | -85.71% |
| 1997-12-31 | $6.50 Million | $-4.20 Million | -0.646x | +0.14% |
| 1996-12-31 | $5.10 Million | $-3.30 Million | -0.647x | -- |
About Novavax Inc
Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally. The company commercializes Nuvaxovid, a COVID-19 vaccine; and R21 Matrix-M adjuvant malaria vaccine. It has license and collaboration agreements with Sanofi, Pfizer Inc., Takeda Pharmaceutical Com… Read more